Published in Cell Adh Migr on January 28, 2013
Survival or death: disequilibrating the oncogenic and tumor suppressive autophagy in cancer. Cell Death Dis (2013) 0.99
Novel strategies to enforce an epithelial phenotype in mesenchymal cells. Cancer Res (2014) 0.78
Imprinted chromatin around DIRAS3 regulates alternative splicing of GNG12-AS1, a long noncoding RNA. Am J Hum Genet (2013) 0.77
S-phase cell cycle arrest, apoptosis, and molecular mechanisms of aplasia ras homolog member I-induced human ovarian cancer SKOV3 cell lines. Int J Gynecol Cancer (2014) 0.75
Involvement of AF1q/MLLT11 in the progression of ovarian cancer. Oncotarget (2017) 0.75
Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. BMC Cancer (2016) 0.75
Rho, rac, and cdc42 GTPases regulate the assembly of multimolecular focal complexes associated with actin stress fibers, lamellipodia, and filopodia. Cell (1995) 24.99
Regulation of cancer cell motility through actin reorganization. Cancer Sci (2005) 3.87
RhoA inactivation by p190RhoGAP regulates cell spreading and migration by promoting membrane protrusion and polarity. Mol Biol Cell (2001) 3.54
Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer (2000) 2.73
The adaptor protein paxillin is essential for normal development in the mouse and is a critical transducer of fibronectin signaling. Mol Cell Biol (2002) 2.73
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest (2008) 2.63
Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene (2010) 1.86
VEGF-induced vascular permeability is mediated by FAK. Dev Cell (2012) 1.85
Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene (2005) 1.80
Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer (2008) 1.75
Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells. Cancer Res (2007) 1.67
Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res (2009) 1.55
Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia (2007) 1.49
Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6. Mol Cell Biol (2007) 1.41
Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res (2009) 1.32
SD-1029 inhibits signal transducer and activator of transcription 3 nuclear translocation. Clin Cancer Res (2006) 1.32
Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2. Neuro Oncol (2008) 1.27
Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J Carcinog (2007) 1.25
Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res (2004) 1.22
MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev Res (Phila) (2010) 1.22
Osteopontin increases migration and MMP-9 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Physiol (2009) 1.16
Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. Methods Enzymol (2006) 1.12
Anticancer properties of the IL-12 family--focus on colorectal cancer. Curr Med Chem (2010) 1.12
Integrin β5 contributes to the tumorigenic potential of breast cancer cells through the Src-FAK and MEK-ERK signaling pathways. Oncogene (2012) 1.11
The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene (2011) 1.11
Celastrol acts as a potent antimetastatic agent targeting beta1 integrin and inhibiting cell-extracellular matrix adhesion, in part via the p38 mitogen-activated protein kinase pathway. J Pharmacol Exp Ther (2010) 1.11
ILK: a pseudokinase in the center stage of cell-matrix adhesion and signaling. Curr Opin Cell Biol (2012) 1.10
CTGF enhances migration and MMP-13 up-regulation via alphavbeta3 integrin, FAK, ERK, and NF-kappaB-dependent pathway in human chondrosarcoma cells. J Cell Biochem (2009) 1.08
IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. Oncol Rep (2010) 1.06
Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. Cancer Res (2011) 1.06
Lysyl oxidase regulates actin filament formation through the p130(Cas)/Crk/DOCK180 signaling complex. J Cell Biochem (2006) 1.06
Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves alphav integrins and the participation of MMP2. Int J Cancer (2005) 1.05
Effects of IL-6 and AG490 on regulation of Stat3 signaling pathway and invasion of human pancreatic cancer cells in vitro. J Exp Clin Cancer Res (2010) 1.05
Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res (2010) 1.04
N-cadherin expression level modulates integrin-mediated polarity and strongly impacts on the speed and directionality of glial cell migration. J Cell Sci (2012) 1.03
Role of MMP-2 in the regulation of IL-6/Stat3 survival signaling via interaction with α5β1 integrin in glioma. Oncogene (2012) 1.03
Kallikrein-related peptidase 7 promotes multicellular aggregation via the alpha(5)beta(1) integrin pathway and paclitaxel chemoresistance in serous epithelial ovarian carcinoma. Cancer Res (2010) 1.00
Osmotic stress and the cytoskeleton: the R(h)ole of Rho GTPases. Acta Physiol (Oxf) (2006) 0.98
A conserved lipid-binding loop in the kindlin FERM F1 domain is required for kindlin-mediated αIIbβ3 integrin coactivation. J Biol Chem (2012) 0.97
RhoA and Rac1 GTPases mediate the dynamic rearrangement of actin in peripheral glia. Development (2003) 0.95
Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk. Cancer Epidemiol (2012) 0.95
Characterization of interactions of adapter protein RAPL/Nore1B with RAP GTPases and their role in T cell migration. J Biol Chem (2007) 0.95
Integrin α6β4 cooperates with LPA signaling to stimulate Rac through AKAP-Lbc-mediated RhoA activation. Am J Physiol Cell Physiol (2011) 0.94
Interleukin-6/interleukin-6 receptor pathway as a new therapy target in epithelial ovarian cancer. Curr Pharm Des (2012) 0.94
Alpha9beta1 integrin in melanoma cells can signal different adhesion states for migration and anchorage. Exp Cell Res (2009) 0.93
IL-6 regulates MMP-10 expression via JAK2/STAT3 signaling pathway in a human lung adenocarcinoma cell line. Anticancer Res (2009) 0.93
Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome. Hum Mutat (2009) 0.93
Integrin adhesions: who's on first? What's on second? Connections between FAK and talin. Cell Adh Migr (2012) 0.90
Effects of Longevinex (modified resveratrol) on cardioprotection and its mechanisms of action. Can J Physiol Pharmacol (2010) 0.88
Endothelial cell-specific molecule 2 (ECSM2) localizes to cell-cell junctions and modulates bFGF-directed cell migration via the ERK-FAK pathway. PLoS One (2011) 0.87
A prognostic gene signature in advanced ovarian cancer reveals a microfibril-associated protein (MAGP2) as a promoter of tumor cell survival and angiogenesis. Cell Adh Migr (2010) 0.86
Norepinephrine promotes the β1-integrin-mediated adhesion of MDA-MB-231 cells to vascular endothelium by the induction of a GROα release. Mol Cancer Res (2011) 0.86
Degradation of internalized αvβ5 integrin is controlled by uPAR bound uPA: effect on β1 integrin activity and α-SMA stress fiber assembly. PLoS One (2012) 0.86
Prognostic value of beta1-integrin (=CD29) in serous adenocarcinomas of the ovary. Anticancer Res (2001) 0.86
The human ARHI tumor suppressor gene inhibits lactation and growth in transgenic mice. Cancer Res (2000) 0.86
Cryptococcus neoformans activates RhoGTPase proteins followed by protein kinase C, focal adhesion kinase, and ezrin to promote traversal across the blood-brain barrier. J Biol Chem (2012) 0.84
Constitutive activation of BMP signalling abrogates experimental metastasis of OVCA429 cells via reduced cell adhesion. J Ovarian Res (2010) 0.83
The role of mechanical stretching in the activation and localization of adhesion proteins and related intracellular molecules. J Cell Biochem (2011) 0.83
Protein kinase G signaling disrupts Rac1-dependent focal adhesion assembly in liver specific pericytes. Am J Physiol Cell Physiol (2011) 0.82
Prognostic role of integrin β1, E-cadherin, and rac1 expression in small cell lung cancer. APMIS (2011) 0.82
Interaction of integrin receptors with extracellular matrix is involved in trophoblast giant cell migration in bovine placentomes. Placenta (2003) 0.82
Role of α5β1 and αvβ3 integrins in relation to adhesion and spreading dynamics of prostate cancer cells interacting with fibronectin under in vitro conditions. Cell Biol Int (2012) 0.81
RhoA GTPase regulates radiation-induced alterations in endothelial cell adhesion and migration. Biochem Biophys Res Commun (2011) 0.81
Integrin alphavbeta3 mediates upregulation of epidermal growth-factor receptor expression and activity in human ovarian cancer cells. Int J Biochem Cell Biol (2008) 0.81
ECM-dependent mRNA expression profiles and phosphorylation patterns of p130Cas, FAK, ERK and p38 MAPK of osteoblast-like cells. Cell Biol Int (2010) 0.80
Integrin αvβ3 promotes vitronectin gene expression in human ovarian cancer cells by implicating rel transcription factors. J Cell Biochem (2011) 0.80
Hyperphosphorylated FAK Delocalizes from Focal Adhesions to Membrane Ruffles. J Oncol (2010) 0.79
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol (2007) 4.06
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol (2008) 3.54
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol (2005) 3.15
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
A genetically defined model for human ovarian cancer. Cancer Res (2004) 3.02
Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res (2005) 2.98
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol (2010) 2.71
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A (2006) 2.64
The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest (2008) 2.63
National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem (2008) 2.44
Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol (2005) 2.34
Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol (2004) 2.32
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res (2005) 2.29
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park) (2013) 2.17
Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol (2010) 2.05
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog (2008) 2.01
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem (2003) 1.91
Early detection of ovarian cancer. Dis Markers (2007) 1.77
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol (2003) 1.75
Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology (2012) 1.71
Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer (2008) 1.69
Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68
Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol (2008) 1.58
The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem (2003) 1.56
The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer (2006) 1.55
Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol (2010) 1.54
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer (2011) 1.53
Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle (2010) 1.48
Project Zero Delay: a process for accelerating the activation of cancer clinical trials. J Clin Oncol (2009) 1.47
Individualized care for patients with cancer - a work in progress. N Engl J Med (2004) 1.42
SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell (2010) 1.42
Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel. Cancer Res (2011) 1.37
Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res (2004) 1.36
Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res (2003) 1.35
Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J Med Chem (2011) 1.34
Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst (2010) 1.33
HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle (2005) 1.33
How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. J Clin Oncol (2007) 1.29
Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem (2003) 1.27
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol (2007) 1.26
Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res (2006) 1.24
Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol (2011) 1.24
ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene (2003) 1.23
Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res (2004) 1.22
Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res (2003) 1.22
The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenviron (2010) 1.21
Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res (2005) 1.20
Early detection of ovarian cancer. Biomark Med (2008) 1.20
Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann N Y Acad Sci (2003) 1.18
Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum Mol Genet (2003) 1.15
Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol (2010) 1.14
Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol (2011) 1.12
Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. Methods Enzymol (2006) 1.12
Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res (2003) 1.12
Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis (2006) 1.11
Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol (2009) 1.10
Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells. Mol Cancer Ther (2007) 1.09
Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res (2002) 1.08
Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem (2004) 1.08
MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation (2008) 1.07
Dasatinib induces autophagic cell death in human ovarian cancer. Cancer (2010) 1.07
Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol (2008) 1.06
Src family kinases and paclitaxel sensitivity. Cancer Biol Ther (2011) 1.05
Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB. J Biol Chem (2003) 1.04
FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. Cancer Res (2011) 1.04
Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res (2006) 1.04
Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Cell Cycle (2006) 1.03
Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol (2007) 1.03
More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. Gynecol Oncol (2011) 1.02
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol (2003) 1.01
Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res (2004) 1.01
Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. BMC Cancer (2011) 0.99
Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene (2003) 0.99
Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer. PLoS One (2012) 0.99
CA125/MUC16 is dispensable for mouse development and reproduction. PLoS One (2009) 0.98
Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle (2008) 0.98
Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res (2003) 0.98
Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res (2003) 0.96
Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer (2012) 0.96
A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther (2009) 0.96
Low-grade serous carcinoma: new concepts and emerging therapies. Gynecol Oncol (2013) 0.95
Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol (2003) 0.94
Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer (2010) 0.93
Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells. Cancer Lett (2012) 0.93
The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J Natl Cancer Inst (2011) 0.92
Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway. Int J Oncol (2013) 0.91
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. Int J Gynecol Cancer (2016) 0.91